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Many institutionalized patients and their healthcare providers are dissatisﬁed with current laxative therapy. This study compared
therapeutic eﬃcacy, safety, and laxative cost of an herbal formula (CCH1) and lactulose for long stay patients with constipation.
In this double-blind, double-dummy, and placebo-controlled trial, we randomized 93 residents with chronic constipation from
two long-term care facilities in Taiwan to receive either CCH1 with lactulose placebo or CCH1 placebo with lactulose for 8 weeks,
then followed up for 4 weeks without study medication. Both treatments were eﬀective and well tolerated for patients, but CCH1
produced more spontaneous bowel movements, less rectal treatments, less amount of rescue laxative, and lower laxative cost than
lactulose during treatment. No signiﬁcant diﬀerences were found in stool consistency, stool amount, global assessment, and safety
concerns. In conclusion, our results suggest that CCH1 may have better eﬃcacy and could be used as an alternative option to
lactulose in the treatment of constipation in long-term care.
1.Introduction
Constipation is often dismissed as a trivial medical concern,
itcanbeassociatedwithmild-to-extremedistressing andpo-
tentially dangerous complications [1]. Almost half of all
patients older than 65 reported constipation or the regular
useoflaxatives[2].Innursingfacilities,72.7%ofthepatients
had at least one precipitating comorbid condition for con-
stipation, and 77.6% of the residents were receiving at least
one medication that may contributed to the occurrence of
constipation [3]. Accordingly, the prevalence of constipation
is higher in long-term care with up to 74% of nursing home
residents using daily laxatives [4]. In fact, constipation often
leads to deterioration in health-related quality of life [5]a n d
also increases time and economic cost of constipation care in
long stay [6].
Dissatisﬁed with conventional therapy, there is a trend
that herbal medicine use increased substantially in the Unit-
ed States, and over one in three Americans used complemen-
tary and alternative medicine (CAM) in the past year [7]. In
Taiwan, more than 95% of citizens have medical insurance
under the national health insurance (NHI) system. The use
of Chinese medicine is also reimbursed by the NHI, and
all qualiﬁed residents in Taiwan are free to choose either
Western medicine or traditional Chinese medicine (TCM)
[8]. A national survey in Taiwan reported 152,564 subjects2 Evidence-Based Complementary and Alternative Medicine
who visited TCM clinics only for constipation during 2004
[9]. Constipation is also of the top three main diagnoses in a
Traditional Medicine Center of a general hospital in Taiwan
[10].
In fact, TCM has been the primary system of medicine
in Asia for thousands of years. According to the theories of
TCM, constipation can be generally divided into excessive
and deﬁcient syndromes (ying, yang, Qi or blood deﬁciency),
based on the underlying etiology [11, 12]. With regard to
the syndrome of yang deﬁciency, it is a pathological state re-
sulting from deﬁciency of “yang” energy with reduction in
its warming and activating power that leads to diminished
functions (including GI system), decreased metabolic activi-
ties, intolerance to cold, and so on [13, 14]. “Wen-Pi Tang”,
derived from a classic TCM book named Qian Jin Fang
(chapter 15) in the Tang Dynasty (A.D. 652), is a famous
formula that has been commonly used throughout Asia for
constipation of the “yang deﬁciency” type [15, 16]. It was
composed of ﬁve herbs (Ren Shen, Gan Jiang, Zhi Fu Zi, Da
Huang,andGanCao)[15,16].Throughthecombinedaction
of these herbs, Da Huang served as purgative drug with the
assistant of the rest of four herbs formulated to strengthen
the energy of yang [14, 16]. From the viewpoints of TCM,
the majority of patients with constipation of yang deﬁ-
ciency are the frail older people or chronically ill patients
[11, 15]. Since many residents in nursing homes are the
dependently older people with comorbidities, most of their
constipation could be attributed to yang deﬁciency in some
degree. Therefore, our previous randomized placebo-con-
trolled trail has demonstrated CCH1 (Table 1), an herbal
formula modiﬁed from “Wen-Pi Tang”,t ob es a f ea n de f f e c t -
ive on the treatment of constipation for the population in
nursing homes [17].
Despite the enthusiasm for CAM, the high-quality com-
parative study of herbal supplements and western medicine
for constipation is limited [18, 19]. From the review of
literature, osmotic laxatives are eﬀective in older adults and
well tolerated [1, 20]. in the UK, the most commonly used of
osmotic agents is lactulose [21], which is also popularly used
inTaiwan.therefore,weaimedtocomparetheeﬃcacy,safety,
and cost of CCH1 and lactulose for treating constipation in
Long-Term Care.
2.MaterialsandMethods
2.1. Participants. The participants were the residents of two
nursing homes in mid Taiwan. They received usual medical
care from one surrounding teaching hospital in the same
community. The study was conducted from August 2008
through April 2010. The inclusion and exclusion criteria are
shown in Table 2.
The study was performed in compliance with the prin-
ciples of the Declaration of Helsinki and following “good
clinical practice” guidelines. The study protocol was ap-
provedbytheResearchEthicsCommitteeofNationalTaiwan
University Hospital before conducted.
2.2. Study Medication. The herbal preparation was ob-
tained from Sun Ten international pharmaceutical company,
Table 1: The composition of CCH1.∗
Manderin
pronunciation Botanical name Gram
Ren Shen Panax ginseng C. A. Meyer 0.8
Gan Jiang Zingiber oﬃcinale Rosc. 0.8
Gan Cao Glycyrrhiza uralensis Fisch. 0.8
Bai Zhu Atractylodes macrocephala Koide. 0.8
Z h iF uZ i Aconitum carmichaeli Debx. 0.8
Da Huang Rheum tanguticum Maxim. ex Balf. 1.2
∗Every 3.0g extract powder are prepared from the above raw herbs.
aqualiﬁedmanufacturerofconcentratedherbalextractswith
good manufacturing practice. The herbs were authenticated
at the Brion Research Institute in Taiwan on the basis of
standards speciﬁed in the Taiwan Pharmacopoeia of Chinese
Medicine (2004 edition). Contamination screening for heavy
metals, pesticides, and aﬂatonix was performed to ensure
safety for human consumption. For quality control and
standardization of CCH1, herbal preparation was performed
in a single batch to ensure consistency of quality. The indica-
tor ingredient of CCH1 was analyzed by high-performance
liquid chromatography (HPLC). After decoction and extrac-
tion, herbal preparation was concentrated into the powdered
f o r ma n dp a c k e di ns e a l e do p a q u ea l u m i n u mf o i lb a g s .
With the reference of a double-blind, and placebo-
controlled trial of an herbal formula [22], the placebo of
CCH1 was made of similarly colored starch, which was
packed in an identical package and manufactured by the
same company as CCH1. With the other reference of a
study for elderly constipated patients, 50% of glucose water
was used as placebo-controlled of lactulose [23]. For similar
viscosity and taste with lactulose, the placebo of lactulose
in our study was manufactured by the same company as
lactulose syrup, which was composed of 500mg glucose,
2mg xanthum gum (a polysaccharide used as a food additive
to increase the viscosity of a liquid), 0.01mg Sunset yellow
FCF (an artiﬁcial coloring allowed to be added to food),
and 497.99mg puriﬁed water in each gram content. For the
ingredientsofplacebointhisstudy,noknownlaxativeeﬀects
or drug interaction with study medication existed.
2.3. Study Design. This double-blind, double-dummy, and
placebo-controlled study had two parallel groups with a total
treatment phase of 8 weeks. After 8 weeks of treatment,
patients were followed up for one additional month without
study medication (CCH1 or lactulose) and placebo except
for rescue laxative of magnesium oxide (MgO). To obtain
baseline information, all patients had a run-in period of 2
weeks without laxatives but only concurrent use of CCH1
placebo and lactulose placebo for ethical concerns and test
for compliance before randomization.
With the reference of the national guidelines of the
Registered Nurses Association [24], daily stool diaries were
kept by the certiﬁed nurse assistants from the beginning of
the run-in period to the completion of the study, including
stool frequency, stool consistency, stool amount, and the
use of rectal treatment (RT; enema, suppository use, orEvidence-Based Complementary and Alternative Medicine 3
Table 2: Inclusion and exclusion criteria.
Inclusion criteria
Age, 20 years and older
Colonic evaluation (colonoscopy or barium enema) within the previous 5 years or regular followup at gastrointestinal clinic
Chronic constipation conﬁrmed by at least one of the following three criteria:
Meeting Rome III criteria of constipation
Receiving enema, suppository, or digital maneuver at least once a week in the past three months
Laxative use in more than half time of the last three months
Exclusion criteria
Known cause of colorectal obstruction or structural lesions (e.g., intestinal neoplasm, anal abscess, anal ﬁstula, anal ﬁssure, rectocele,
and megacolon)
Inﬂammatory bowel disease
Irritable bowel syndrome
Hypothyroidism
Spinal cord injury
Muscular dystrophy
Known severe hepatic or renal insuﬃciency (e.g., liver cirrhosis or receiving hemodialysis)
Unknown cause of gastrointestinal bleeding or acute infection
Exposure to any other investigational drug within 30 days prior to enrollment
History of allergy to the composition of the study medication
New onset or unstable psychiatric disorders
Pregnancy or breastfeeding
History of alcohol or drug abuse
Any condition associated with poor compliance with medical treatment
digital maneuver). Stool consistency was recorded by Bristol
Stool Form Scale, ranging from 1 (separate hard lumps,
like nuts) to 7 (watery, no solid pieces) [25]. Stool amount
was classiﬁed into three categories (small, moderate, and
large) according to the national guidelines [24]. In addition,
a bowel routine protocol was set: if there was no bowel
movement(BM)byday3,thecaregivergaveasuppositoryof
bisacodyl or glycerin ball on day 3; if there was no BM after 8
hoursofsuppositoryinsertion,enemawasgiven.Meanwhile,
when necessary, the caregiver could apply a digital maneuver
to manually remove the hard stool or stimulate the rectum.
Therefore, the bowel performance kept in the stool diary
could imply the severity of constipation clinically.
Considering of the real situation in long-term care, phy-
sicians usually prescribe laxatives with diﬀerent dosage ac-
cording to the severity of constipation based on the stool
diary. The participants were classiﬁed into three groups for
initial dosage of study medication by enema frequency and
weekly spontaneous bowel movement (SBM) during the
run-in period. Having enema more than once a week was
regarded as group A. Residents who received enema once a
week or had less than three SBMs per week belonged to the
group B. The frequency of SBM three to seven times a week
was referred to as group C. Participants averaging more than
one SBM per day during the run-in period were excluded.
Residents were randomized to the study medication ac-
cording to a computer-generated randomization schedule.
Randomization was stratiﬁed based on the severity of con-
stipation and Barthel’s index [26], a scale used to measure
functional performance in basic activities of daily living.
Allocation concealment was performed by enclosing assign-
ments in sequentially numbered, identical, and sealed two
envelopesaccordingtotheallocationsequenceineverystrat-
iﬁed group. The packaging of study medication and placebo
were indistinguishable, and they were dispensed after ran-
domization by an independent research assistant in a sep-
arate oﬃce. All persons involved in the conduct and man-
agement of the study were blinded to individual patient
treatment during the study.
2.4. Interventions. The experimental group received an ini-
tial dose of 4.5/3.0/1.5gm CCH1 powder with 45/30/15mL
lactulose placebo per day for groups A/B/C, respectively.
The active comparator group was given an initial dose of
45/30/15mL lactulose with 4.5/3.0/1.5gm CCH1 placebo
per day for groups A/B/C, respectively. If optimal bowel
performance [27] (3SBMs/wk to 3SBMs/day without any
rectal treatment) was not reached, study medication were
titratedbyweeklyincrementsof“1.5gmofCCH1and15mL
of lactulose placebo for experimental group” or “15mL of
lactulose and 1.5gm of CCH1 placebo for comparator
group” until the maximal daily dose of 6.0gm for CCH1/
CCH1 placebo or 60mL for lactulose/lactulose placebo.
Daily dosage over 3.0gm of CCH1/CCH1 placebo or over
30mLoflactulose/lactuloseplacebowasprescribedbydivid-
ed dose.
During the whole study period of 12 weeks, MgO was the
only rescue oral laxative allowed to be used. In the treatment4 Evidence-Based Complementary and Alternative Medicine
phase of weeks 1–8, if optimal bowel performance was not
reached under the maximal dose of study medication, MgO
was added by the blinded primary physician and was titrated
every week (increased by up to 750mg/day once a week,
maximum dose of 2.0g/day).
2.5. Assessment. Participants were visited every week by one
primary physician with licenses for both conventional med-
icine and TCM during the entire study period of 12 weeks.
SBM was deﬁned as stool passage without digital maneuver
and without the use of suppository or enema on the same
day. The cost calculations of lactulose and MgO were de-
rived from the reimbursed payment of the national health
insurance in Taiwan. The cost assigned to the investiga-
tional product (CCH1) was derived from current wholesale
distributor pricing. Using a 5-point Likert scale, the global
assessment of eﬃcacy was evaluated by patients themselves
or their principal caregivers if their cognition was impaired.
2.6. Eﬃcacy. The frequency of SBM during weeks 1–4, 5–
8, and 9–12 was measured as primary eﬃcacy. Secondary
end points included (1) frequency of RT during weeks 1–
4, 5–8, and 9–12; (2) weekly amount of rescue laxative use
during weeks 1–4, 5–8, and 9–12; (3) weeky laxative cost
during treatment phase of weeks 1–4 and 5–8; (4) average
score of Bristol Scale during weeks 1–4, 5–8, and 9–12; (5)
meanproportionofdiﬀerentstoolamount(small,moderate,
and large) per week during weeks 1–4, 5–8, and 9–12; (6)
global assessment of eﬃcacy at the end of treatment phase;
(7) cumulative incidence of adverse events during the entire
study period.
2.7. Safety. Safety evaluations included adverse events and
serious adverse events reporting, vital signs, physical exam-
ination ﬁndings, and laboratory results. Adverse events were
monitored with a comprehensive symptom questionnaire as
well as clinical laboratory testing—including complete blood
count, plasma sugar, aspartate aminotransferase, alanine
aminotransferase, total bilirubin, alkaline phosphatase, urea
nitrogen,creatinine,albumin,thyroid-stimulatinghormone,
freethyroxine,sodium,potassium,calcium,phosphate,mag-
nesium,uric acid,triglyceride,andtotal cholesterol—carried
out before and after treatments in a qualiﬁed laboratory.
2.8. Statistical Analysis. An intention to treat analysis was
conducted on all patients randomized for therapy. All pa-
tients who had taken at least one dose of study medication
after randomization were included in the safety analysis. A
last observation carried forward analysis was conducted for
any missing data of primary or secondary outcomes except
globalassessmentofeﬃcacyandadverseevents.Sinceprima-
ry eﬃcacy and some secondary end points were to measure
the outcomes at diﬀerent time periods, the Bonferroni ad-
justment for multiple comparisons was used to assess the
statistical signiﬁcance of these multiple tests. Statistical anal-
ysis was performed using SPSS software version 13 (SPSS,
Chicago, IL, USA). Numerical data were compared using the
Student’s t-test or Mann-Whitney U test. The paired t-test
was used to compare individual bowel performance before
and after treatment. A χ2 test or Fisher exact test where ap-
propriate were used to compare the number of patients with
adverse events, global assessment of eﬃcacy, and categorical
data of patients’ characteristics in baseline period between
two groups. These comparisons were made at a 2-sided α
level of 0.05.
2.9. Sample Size Considerations. Based on previous clinical
trial of CCH1 and the methodological recommendations of
as y s t e m a t i cr e v i e w[ 17, 21], the standard deviation of the
mean weekly SBM was estimated to be 2.0. A total sample
size of about 93 patients would be required to detect a mean
diﬀerence between treatments of 1.5 bowel movements per
week under the assumptions of 90% power, a 2-sided α value
of 0.05 and allowance for a 20% drop-out rate.
3. Results
3.1. Participants, Study Conduct, and Completion. At o t a lo f
120 participants who had signed the informed consent were
screened for eligibility; 93 (77.5%) met the inclusion criteria
and were randomized. The reasons for exclusion are shown
in Figure 1. Over 80% of the 93 enrolled patients were older
than 60 years with mean age of 73.5 and 54.8% were female.
Patients’ baseline characteristics were similar between the
two treatment groups (all P<0.05; Table 3). A total of 20
(21.5%) patients dropped out of the trial during the treat-
ment phase (weeks 1–8): 5 (11.4%) in the CCH1 group and
15 (30.6%) in the lactulose group (P = 0.041). Among the
15 dropouts in lactulose group, 8 people had severe adverse
events and hospitalized (pneumonia: 2, acute gastroenteritis:
2, upper gastrointestinal bleeding: 1, urinary tract infection:
1,ileus:1,andcellulitis:1);2personswithdrewtheirconsents
and one of them complained lactulose syrup was too sweet;
2 residents were lost to followup because transferred to
other facilities; one person was withdrawn on the ethical
concerns for refractory constipation under the maximum
dosage of treatment medication and rescue laxative; another
2 persons were dropped from the study for poor compliance
(Figure 1). Thirty-four (77.3%) patients in the CCH1 group
and 29 (59.2%) patients in the lactulose group completed
the study (P = 0.077). There was no signiﬁcant diﬀerent on
demographics between drop outs and nondrop outs.
3.2. Primary Eﬃcacy Analysis. During treatment phase,
mean daily dose of study medication was 3.8 (standard devi-
ation1.4)gramCCH1inexperimentalgroupand38(SD14)
mL lactulose in comparator group. No signiﬁcant diﬀerences
were found in the frequency of SBM in baseline period
between the two groups (mean diﬀerence 0.1 [95% CI −0.9
to 1.0]). Mean numbers of weekly SBM in CCH1 group were
greater than those in lactulose group during 8-week treat-
ment phase (6.8 versus 5.0, diﬀerence 1.8 [0.7 to 3.0]; P =
0.001); greatest diﬀerence was during weeks 1–4 (6.9 versus
4.5, diﬀerence 2.4 [1.2 to 3.6]; P<0.001). However, in the
follow-up phase of weeks 9–12, the frequency of SBM in
CCH1 group was less than that in lactulose group (3.7 versusEvidence-Based Complementary and Alternative Medicine 5
27 discontinued during screening or 
run-in periods:
  4  protocol violation 
  4  withdrew consent 
  1  no longer required treatment  
  3  admission                 
  15  other 
5 discontinued treatment phase:
  3  adverse events 
  1  withdrew consent 
  0  lost to followup 
  1  administrative problems
15 discontinued treatment phase:
  8  adverse events 
  2  withdrew consent 
  2  lost to followup 
  3  administrative problems
5 discontinued followup phase:
  5  adverse events 
  0  lost to followup 
5 discontinued followup phase:
  3  adverse events 
  2  lost to followup 
120 assessed for eligibility
93 randomized
44 allocated to
Chinese herb 
39 completed 8-weeks
double-blind Tx
49 allocated to
lactulose
34 completed
4 more weeks F/U
44 analyzed
34 completed 8-weeks
double-blind Tx
29 completed
4 more weeks F/U
49 analyzed
Figure 1: Participant ﬂowchart depicting the randomization, treatment, and followup in CCH1 and lactulose groups.
5.2; P = 0.084),but still greater than its baseline period (3.7
versus 2.7; P = 0.005) (Table 4).
3.3. Secondary End Points. Smaller mean numbers of RT/wk
were observed in the CCH1 group compared with the
lactulose group during weeks 1–4 (0.5 versus 0.9, diﬀerence
−0.4 [−0.7 to −0.1]) and weeks 5–8 (0.3 versus 0.6, differ-
ence −0.3 [−0.5 to −0.1]). Regarding the need for a rescue
laxative (MgO), the mean numbers of tablets of MgO/wk
were less for the patients who were given CCH1 than for
those who received lactulose during the entire treatment
phase; the greatest diﬀerence was during weeks 5–8 (1.7
versus 10.4, diﬀerence −8,7 [−13.4 to −3.9]). However, no
signiﬁcant diﬀerences were found in the frequency of RT/wk
(1.0 versus 0.8) or in the amount of MgO/wk (19.1 versus
20.0) between the two groups during follow-up phase of
weeks 9–12 (Table 4).
Compared with the lactulose group, the laxative cost
(USD/wk) in CCH1 group was less during weeks 1–4 (1.4
versus 4.7, diﬀerence −3.3 [−3.8 to −2.8]) and weeks 5–8
(1.5 versus 5.0, diﬀerence −3.5 [−4.2 to −2.8]) (Table 4).
No signiﬁcant diﬀerences were found in stool consistency
or stool amount between the two groups at all time points
(Table 5). The 73 (78.5%) patients who completed the treat-
ment phase were investigated for global assessment of ef-
ﬁcacy at week 8, 84.6% of CCH1 patients had marked or
slightly improvement versus 79.4% in the lactulos group
(P = 0.646) (Table 6).
3.4. Safety and Compliance. All patients in both groups had
good compliance of around 97% with study medication
except for three patients with 70–80% (Table 7). Six (13.6%)
in CCH1 and 12 (24.5%) in lactulose patients discontinued
thestudybecauseofsevereadverseevents(SAEs)(P = 0.203;
Table 8). No signiﬁcant diﬀerences were found between the
two groups in the incidence of any one of the common AEs
or SAEs (Tables 8 and 9).
4. Discussion
In this randomized, double-blind, double-dummy, and pla-
cebo-controlled trial, we found that both CCH1 and lactu-
lose are eﬀective and well tolerated in long stay patients with
constipation.However,theregimenofCCH1producedmore
frequent SBM, less frequent RT, lower amount of rescue lax-
ative, and lower laxative cost than lactulose during treatment
of 8 weeks.
In TCM, “syndromes” are the foundations for therapeu-
tic principles [11]. However, to date there is no international
consensus or consistently applied classiﬁcation or criteria of
syndromes for many diseases and symptoms such as consti-
pation [28]. And the process of syndrome identiﬁcation per-
formed by TCM doctors is very subjective and usually lacks
interrater consistency because it is highly dependent on
the TCM doctors’ personal skills including evaluating the
nature of patient’s pulse and appearance of the tongue [28].
That is why clinical trials of TCM are often questionable6 Evidence-Based Complementary and Alternative Medicine
Table 3: Characteristics of patients in baseline period.
Variables
Group, number (%) P value
CCH1 Lactulose
Gender
Female 26 (59.1) 25 (51.0) 0.43
Male 18 (40.9) 24 (49.0)
Age (years)
41–60 9 (20.5) 9 (18.4)
0.59 61–80 17 (38.6) 24 (49.0)
>80 18 (40.9) 16 (32.7)
Mean (SD) 73.4 (13.3) 73.6 (13.2) 0.94
Abdominal surgery
No 30 (68.2) 38 (77.6) 0.30
Yes 14 (31.8) 11 (22.4)
Barthel index∗
≤30 31 (70.5) 37 (75.5)
0.83 35–60 6 (13.6) 5 (10.2)
>60 7 (15.9) 7 (14.3)
Median (25th, 75th percentile) 17.5 (0, 45) 10.0 (0, 32.5) 0.59
Severity of constipation†
Group A 21 (47.7) 23 (46.9)
0.84 Group B 15 (34.1) 19 (38.8)
Group C 8 (18.2) 7 (14.3)
History of disease
Hypertension 30 (68.2) 29 (59.2) 0.36
Cerebrovascular disease 22 (50.0) 29 (59.2) 0.37
Diabetes 15 (34.1) 17 (34.7) 0.95
Cardiovascular disease 12 (27.3) 16 (32.7) 0.57
Dementia 9 (20.5) 9 (18.4) 0.79
Anxiety/depression 7 (15.9) 12 (24.5) 0.30
Chronic lung disease 6 (13.6) 5 (10.2) 0.60
Peptic ulcer 4 (9.1) 7 (14.3) 0.43
Anemia 3 (6.8) 5 (10.2) 0.71
Parkinsonism 2 (4.5) 7 (14.3) 0.16
Malignancy except GI origin 2 (4.5) 3 (6.1) 0.99
Chronic hepatitis 2 (4.5) 3 (6.1) 0.99
Chronic kidney disease 1 (2.3) 3 (6.1) 0.61
∗Barthel index [26] (0–100) is a scale used to measure performance in basic activities of daily living. A higher number is associated with a better performance.
†Participants were classiﬁed into three groups according to their bowel performance in the run-in period under the bowel routine protocol in long-termc a r e :
g r o u pA :r e c e i v e de n e m am o r et h a no n c eaw e e k ,
group B: received enema once a week or had less than three times of spontaneous bowel movements per week,
group C: 3–7 times of spontaneous bowel movements per week under usual care.
about whether the study results are reproducible for other
research teams or generalizable to the Western patients [29].
By contrast, in our study, the majority of study population in
long-term care was estimated to be the pattern of yang
deﬁciency in terms of TCM theories [15]. Therefore, without
the need to or help of TCM practitioners, this study is easier
to be replicated or translated into routine care of constipa-
tion in conventional medicine. However, the relationship of
therapeuticeﬀectofCCH1withthedegreeofyang deﬁciency
in long stay residents needs to be investigated.
From literature review, there is no consistently applied
deﬁnition of constipation in the elderly [30]. Deﬁnition such
as the Rome III criteria, however, may not encompass the
perceptions of all patients with constipation [20]. Patients’
deﬁnitions are often qualitative and include stool consist-
ency, diﬃculty with passage, requirement of manual, medic-
inal, or other maneuvers to evacuate feces [31, 32]. In ad-
dition, constipation is often multifactorial in origin (includ-
ing primary and secondary causes) with mixed types of
pathophysiology in long-term care [33]. And the long stayEvidence-Based Complementary and Alternative Medicine 7
Table 4: Comparison of the treatment eﬀect between CCH1 and lactulose.
Variables Group, mean (95% CI)
CCH1 (n = 44) Lactulose (n = 49) Adjusted P‡
Frequency of spontaneous bowel movement (SBM/wk)§
Baseline (weeks −2∼0) 2.7 (1.9, 3.4) 2.6 (2.0, 3.2) 0.907
Treatment (weeks 1∼4) 6.9† (6.1, 7.6) 4.5† (3.5, 5.4) <0.001
Treatment (weeks 5∼8) 6.8† (6.0, 7.7) 5.5† (4.5, 6.6) 0.159
Follow-up (weeks 9∼12) 3.7∗ (3.1, 4.4) 5.2† (4.0, 6.4) 0.084
Frequency of rectal treatment (RT/wk)||
Baseline (weeks −2∼0) 1.4 (1.1, 1.8) 1.4 (1.1, 1.7) 0.958
Treatment (weeks 1∼4) 0.5† (0.4, 0.7) 0.9† (0.7, 1.2) 0.030
Treatment (weeks 5∼8) 0.3† (0.2, 0.5) 0.6† (0.4, 0.8) 0.051
Followup (weeks 9∼12) 1.0∗ (0.8, 1.3) 0.8† (0.5, 1.1) 0.561
Amount of rescue laxative use (MgO/wk)
Baseline (weeks −2∼0) 0 (0, 0) 0.4 (−0.1,0.8) 0.083
Treatment (weeks 1∼4) 0.2 (−0.1, 0.5) 2.4∗ (1.1, 3.8) 0.005
Treatment (weeks 5∼8) 1.7 (−0.4, 3.9) 10.4† (6.1, 14.7) 0.002
Followup (weeks 9∼12) 19.1† (14.9, 23.2) 20.0† (14.5, 25.4) 1.000
Laxative cost (USD/wk)¶
Treatment (weeks 1∼4) 1.4 (1.2, 1.5) 4.7 (4.2, 5.2) <0.001
Treatment (weeks 5∼8) 1.5 (1.3, 1.7) 5.0 (4.4, 5.7) <0.001
Pairwise comparisons were performed for each treatment group with its baseline.
∗P<0.01; †P<0.001.
‡P value was adjusted by Bonferroni adjustment.
§SBM (spontaneous bowel movement) deﬁned as stool passage without digital maneuver and without the use of suppository or enema on the same day.
||RT (rectal treatment) including enema, suppository use, or digital maneuver.
¶Laxative cost including the acquisition costs of study medication and rescue laxative.
residents in our study had potentially poor cognitive func-
tion or expression ability. Therefore, we added the other two
inclusion criteria of constipation (“receiving enema, suppos-
itory or digital maneuver” and “laxative use”) to Rome III
criteria, which are composed of several “subjective” com-
plaints for “functional” constipation.
For the classiﬁcation of constipation severity, the resi-
dents who had bowel frequency of 3–7 times a week during
run-in period were referred to as group C (mild constipa-
tion). Although physicians often use the quantitative deﬁ-
nition of <3 bowel movements per week to describe con-
stipation, there is lack of agreement on the deﬁnition of
constipation regarding what patients perceive and what phy-
sicians traditionally see as constipation [1]. Furthermore,
placebo was given in the run-in period, which is associated
with high rates of resolution in a functional bowel disorder
[34]. And variation in symptoms over time is the nature of
functional disorders, which may contribute to the “tempo-
rary” improvement of constipation during run-in period.
Therefore, group C patients are not excluded as the study
design of a previous clinical trial [17].
Moreover, since high percentage of residents in long-
term care had precipitants of constipation including medical
conditions and related medications [3], exclusion of these
patients in clinical trial of constipation in long stay is neither
practical nor ethical. Therefore, we kept the patients and in-
vestigated their medical illness. After randomization, major
diseases in the patients were equally distributed between
both groups as described in Table 3. In addition, for eth-
ical reasons, all medications except laxatives were left for
participants as prescribed before enrolled. Although there
was no detailed record or analysis about every category of
medication that patients used during the study, it is reason-
able to infer that disease-related medications were randomly
distributed and balanced between the two groups as that of
medical illness. However, further study with explicit survey
of related medications is still essential.
For the primary outcome of SBMs, the mean numbers of
weeklySBMinCCH1andlactulosegroupswere6.8±2.2and
5.0 ± 2.9, respectively, during 8-week treatment phase. The
pooled standard deviation was calculated to be 2.6, which is
slightly larger than the assumed one (SD = 2.0) used in the
sample size calculation. However, the observed eﬀect size
here (1.8) is also larger than the expected value of 1.5
bowel movements, making the standardized eﬀect size of 0.7
(1.8/2.6) close to the expected one of 0.75 (1.5/2.0). There-
fore, after calculation by the software package for sample size
andpowerestimationPASS(PowerAnalysisandSampleSize,
Kaysville, UT, USA), we still have the power of 0.91 to tell
the diﬀerence of SBM frequency between the two groups.
With regard to the negative results of secondary outcomes,
although it could be attributed to the lower power (0.1–0.5)
to identify the diﬀerences between groups, some of these
eﬀect sizes observed here were actually small and clinically8 Evidence-Based Complementary and Alternative Medicine
Table 5: Comparison of stool consistency and stool amount between CCH1 (n = 44) and lactulose (n = 49) groups.
Variables
Group, mean (95% CI)
CCH1 Lactulose Adjusted P∗
Average score of bristol scale†
Week −2–0 4.0 (3.8, 4.3) 4.2 (4.0, 4.3) 0.495
Week 1–4 4.7 (4.5, 4.9) 4.5 (4.3, 4.7) 0.475
Week 5–8 4.7 (4.5, 4.9) 4.8 (4.6, 5.0) 1.000
Week 9–12 4.5 (4.3, 4.8) 4.7 (4.5, 4.9) 1.000
Percentage of large stool amount‡
Week −2–0 29.8 (21.5, 38.1) 32.9 (25.4, 40.3) 0.581
Week 1–4 36.6 (30.5, 42.8) 38.3 (30.8, 45.9) 1.000
Week 5–8 42.1 (34.9, 49.2) 38.7 (31.4, 46.0) 1.000
Week 9–12 37.0 (29.8, 44.3) 32.9 (25.2, 40.6) 1.000
Percentage of moderate stool amount‡
Week −2–0 50.5 (42.0, 59.1) 52.9 (44.5, 61.2) 0.692
Week 1–4 52.2 (47.1, 57.4) 49.2 (41.0, 57.4) 1.000
Week 5–8 48.2 (41.9, 54.6) 47.5 (39.9, 55.0) 1.000
Week 9–12 53.2 (46.0, 60.4) 50.9 (42.9, 58.9) 1.000
Percentage of small stool amount‡
Week −2–0 19.7 (13.1, 26.3) 14.2 (8.6, 19.9) 0.211
Week 1–4 11.1 (7.4, 14.8) 12.0 (7.5, 16.4) 1.000
Week 5–8 9.7 (5.6, 13.8) 13.8 (8.9, 18.7) 0.588
Week 9–12 9.8 (6.1, 13.5) 16.2 (11.0, 21.4) 0.142
∗P value was adjusted by Bonferroni adjustment.
†Stool consistency was recorded by Bristol Stool Form Scale [25], ranging from 1 (separate hard lumps, like nuts) to 7 (watery, no solid pieces).
‡Stool amount was classiﬁed into three categories (small, <250g; moderate, 250–500g; large, >500g) according to a national guidelines of the Registered
Nurses Association [24].
Table 6: Global assessment of eﬃcacy.∗,†
Variables
Group, number (%)
P Value
CCH1
(n = 39)
Lactulose
(n = 34)
Marked improved 21 (53.8) 18 (52.9)
0.646
Slightly improved 12 (30.8) 9 (26.5)
Unchanged 5 (12.8) 7 (20.6)
Slightly worse 1 (2.6) 0 (0)
Markedly worse 0 (0) 0 (0)
∗The global assessment of eﬃcacy was evaluated at the end of treatment
phase by patients themselves or their principal caregivers if their cognition
was impaired.
†A total of 20 patients dropped out of the trial during the treatment phase.
insigniﬁcant. Further study with larger sample size may be
needed to identify the signiﬁcance of the outcome measures
with small eﬀect size.
Although the prespeciﬁed LOCF was applied as our an-
alytic method, it could not be the most appropriate way to
deal with the missing data. It is of particular concern that the
dropout rate was diﬀerent between the two groups during
study period. Because more dropouts in the lactulose group
camefrom“adverseevents”andallofthemwerehospitalized
for “severe adverse events”, it is reasonable to infer that these
dropout patients’ constipation would become worse after
Table 7: Compliance for study medication.∗
Study medication
Group, mean (SD)
P Value
CCH1 Lactulose
Powder
CCH1 97.1 (6.4) — 0.772
CCH1 Placebo — 97.4 (5.1)
Syrup
Lactulose — 97.5 (5.1) 0.637
Lactulose Placebo 96.9 (6.4) —
∗TheexperimentalgroupreceivedCCH1powderandlactuloseplacebo.The
active comparator group was given lactulose syrup and CCH1 placebo.
Table 8: Comparison of severe adverse events.
Variables
Group, number (%)
CCH1 Lactulose
Pneumonia 5 (11.4) 5 (10.2)
Upper GI bleeding 1 (2.3) 1 (2.0)
Acute gastroenteritis 0 (0) 2 (4.1)
Cellulitis 0 (0) 1 (2.0)
Urinary tract infection 0 (0) 2 (4.1)
Ileus 0 (0) 1 (2.0)Evidence-Based Complementary and Alternative Medicine 9
Table 9: Comparison of common adverse events (cumulative incidence >5%).
Variables
Group, number (%)
P Value∗
CCH1 Lactulose
Flatulence 16 (36.4) 17 (34.7) 0.867
Albumin ↓ 15 (34.1) 10 (20.4) 0.137
Diarrhea 15 (34.1) 17 (34.7) 0.951
Hiccup 13 (29.5) 12 (24.5) 0.583
Hemoglobin ↓ 12 (27.3) 6 (12.2) 0.067
Abdominal pain 10 (22.7) 8 (16.3) 0.435
Bloating 9 (20.5) 11 (22.4) 0.815
Magnesium ↑ 8 (18.2) 12 (24.5) 0.614
Acid regurgitation 8 (18.2) 8 (16.3) 0.813
URI 8 (18.2) 6 (12.2) 0.424
Red blood cell ↓ 7 (15.9) 4 (8.2) 0.248
Sugar ↑ 6 (13.6) 9 (18.4) 0.536
Calcium ↓ 6 (13.6) 2 (4.1) 0.143
Sodium ↓ 5 (11.4) 2 (4.1) 0.249
Alkaline phosphatase ↑ 4 (9.1) 1 (2.0) 0.186
Albumin ↑ 4 (9.1) 1 (2.0) 0.186
Potassium ↑ 4 (9.1) 4 (8.2) 1.000
Phosphate ↑ 4 (9.1) 1 (2.0) 0.186
Nausea 4 (9.1) 7 (14.3) 0.439
White blood cell ↓ 3 (6.8) 2 (4.1) 0.665
Sugar ↓ 3 (6.8) 2 (4.1) 0.665
Blood urea nitrogen ↑ 3 (6.8) 5 (10.2) 0.718
Dizziness 3 (6.8) 1 (2.0) 0.341
Cough 3 (6.8) 4 (8.2) 0.561
Skin rash 2 (4.5) 3 (6.1) 1.000
Platelet ↑ 2 (4.5) 3 (6.1) 1.000
Aspartate aminotransferase ↑ 2 (4.5) 4 (8.2) 0.680
Alanine aminotransferase ↑ 2 (4.5) 3 (6.1) 1.000
Creatinine ↑ 2 (4.5) 3 (6.1) 1.000
Triglyceride ↑ 2 (4.5) 5 (10.2) 0.440
Vomiting 2 (4.5) 3 (6.1) 1.000
Diaper rash 1 (2.3) 5 (10.2) 0.207
Cholesterol ↑ 1 (2.3) 4 (8.2) 0.365
Cholesterol ↓ 1 (2.3) 3 (6.1) 0.619
Creatine phosphokinase ↑ 0 (0) 3 (6.1) 0.244
Uric acid ↑ 0 (0) 3 (6.1) 0.244
Pruritus 0 (0) 3 (6.1) 0.244
Chest tightness 0 (0) 3 (6.1) 0.244
∗A χ2 test or Fisher exact test where appropriate was used to compare the number of patients with adverse events between two groups.
admission. Our estimation in the outcome variables at end-
point for the lactulose group would result in a better status
under the imputation method of LOCF because of its
assumption that the response remains constant at the last
observed value. Under this condition, the eﬃcacy of CCH1
group would be underestimated. Thus, the biased results in
the eﬀect are toward the null, a lesser threat to validity. In
addition,LOCFwasthemostcommonmethodthatwasused
in the literature [35], and mixed models for handling the
missingdatadonotworkwellduetooursmallsizeofsample
[36].
According to a recent systematic review [18] of 137 stud-
ies on the eﬃcacy of TCM for the management of constipa-
tion, only 21 clinical trials were high of quality with partic-
ipants’ mean age of 50 years and TCM intervention of 20.6
days. Compared with them, our study has older participants
of 73 years and longer intervention of 2 months. Among the
21 clinical trials of high quality, there were eight studies to10 Evidence-Based Complementary and Alternative Medicine
compare TCM with Western medicine, which were all pub-
lished in Chinese, and the results showed that Chinese herbal
medicine were more eﬀective than conventional medicines
(cisapride, mosapride, or phenolphthalein). Compared with
all the active controls selected in the eight studies, only
lactulose used in our study had good supporting evidence
forthe treatmentof chronic constipation [19,37]. Therefore,
CCH1 is the ﬁrst Chinese herbal Medicine, which results
of this study suggesting a better eﬃcacy than lactulose as a
treatment option for constipation in long-term care.
The double-blind, randomized, and placebo-controlled
trial is the gold standard method to test the eﬃcacy of a
new treatment [38]. However, the herbal supplements with
quality placebo-controlled trials to evaluate their eﬀect on
constipation were limited from the literature review [18, 19].
Furthermore, for the long-term care setting, little evidence
is available from high-quality randomized controlled trials
[39]. The tincture of jalapa, derived from a tropical plant in
Brazil, is shown to be eﬀective in the acute treatment of
functional constipation [40]. Yun-chang capsule, a Chinese
herbal formula, is eﬃcacious and safe on the treatment of
functional constipation for patients with deﬁcient syndrome
of Qi and yin [41]. Hemp Seed Pill, a TCM proprietary
medicine, is safe and eﬀective for alleviating functional con-
stipation for subjects in excessive syndrome [35]. The study
population in the three herbal trials was all targeted to the
ambulatory outpatients with mean age of 33–42 years [35,
40, 41]. For the residents in long-term care, Smooth Move
herbal tea, when added to the standard treatment with usual
laxatives, increased bowel movements compared to the addi-
tion of a placebo tea [42]. In comparison with Smooth Move
as a complementary agent for current laxatives, CCH1 in our
study was documented to be a good alternative laxative to
lactulose as ﬁrst-line treatment for long stay patients with
constipation.
Compared with lactulose used in our study, although
polyethylene glycol (PEG) has not been studied in trials
of exclusively geriatric populations [43] ,aC o c h r a n er e v i e w
indicates that PEG is better than lactulose in outcomes of
stool frequency and stool consistency [44]. However, a drug
class review conducted by the FDA noted that high doses
of PEG may produce diarrhea and excessive stool frequency,
particularly in elderly nursing home patients [45]. Lactulose
and the other nonabsorbable sugar, sorbitol, appeared to
be equally eﬃcacious, but sorbitol is recommended as a
cost-eﬀective alternative to lactulose for the treatment of
constipation in the elderly [46]. Lactitol, a widely prescribed
osmotic laxative in India, is also suggested to be preferred
over lactulose for adults with chronic constipation because
of its comparable eﬃcacy, better palatability and lesser in-
cidence of adverse events [47]. In addition, a combination of
senna plus ﬁbre is more cost-eﬀective and eﬃcient than
lactulose in treating constipation in long stay elderly patients
[48]. Therefore, further studies to compare the eﬃcacy,
safety, and cost-eﬀectiveness of CCH1 with other osmotic
agents, including PEG, sorbitol, lactitol, or combination lax-
atives for the treatment of constipation in long-term care are
encouraged.
There are some strengths in our study. The clinical trial
of head-to-head comparison of CCH1 and lactulose was
conducted with a strict and accepted methodological pro-
tocol. Compliance was around 97%, which is excellent for a
trial in older subjects. Furthermore, unlike most randomized
controlled trials for constipation conducted in ideal condi-
tions [39] or in the population of ambulatory community-
dwelling adults [19, 49], this study was conducted in the
real situation without interference with the usual care and
bowel routine for the long-term care residents, who have
many nonmodiﬁable risk factors such as polypharmacy and
coexistent medical conditions. In addition, the clinical trial
fully adheres to the rationale of medical prescription in con-
ventional medicine, which usually prescribing initial dosage
of laxatives based on the severity of constipation, then titrat-
ing according to drug response.
This study has some limitations or weakness. First, test of
success of blinding was not performed in the study. Second,
because the residents in long-term care had potentially
impairedcognitivefunctionorpoorexpressionabilitydueto
old age with frailty, multiple medication, and chronic illness,
objective data from medical records and stool diaries were
used for outcome measurements rather than the subjective
assessment of symptom score or quality of life. Third, the
main population in the study was older adults living in long-
term care. Therefore, the eﬀect of CCH1 for young residents
in long stay or the elderly in the community remains to be
investigated. Fourth, the medical cost in the study was lim-
ited to the pharmacological cost of national health insurance
in Taiwan, which is not generalizable to diﬀerent countries
or diﬀerenthealthinsurancesystems.Moreover,thetruecost
of managing constipation is impacted on by a broad range of
resources and not only laxative acquisition costs [50]. There-
fore, further clinical trials may be necessary to compare the
economic impact of CCH1 with current laxatives, including
time, health providers’ visits, caregivers’ burden, and labor
cost. Fifth, for the considerations of ethical concerns and
real situation in clinical practice, when study medication
was titrated to maximal dose, our study design allowed the
primary physician to add and adjust the dosage of rescue
laxative every week until optimal bowel performance was
observed. Therefore, the laxative eﬀect in the study was
probably attributed to the combined eﬀect of study med-
ication and MgO. In addition, because CCH1 had better
laxative eﬀect than lactulose on SBM during treatment, the
weekly amount of MgO was less in CCH1 group than that
used in the lactulose group during treatment phase and the
beginning of follow-up phase (4.2 versus 14.1 at week 9,
P = 0.002). Therefore, we did not have enough evidence to
compare the maintenance eﬀect of treatment medication by
the study design.
5. Conclusions
In conclusion, both CCH1 and lactulose were eﬃcacious and
well tolerated but CCH1 signiﬁcantly increased spontaneous
bowel movements and concurrently reduced the need of
rectaltreatmentsandadditionallaxativeatlowerlaxativecost
during treatment. Although the maintenance eﬀect of CCH1Evidence-Based Complementary and Alternative Medicine 11
was uncertain, it still suggested good value for new drug de-
velopment. A properly designed large-scale or multicenter
clinical trial with longitudinal dada analysis is essential. Fur-
ther comparative study with other laxatives is also encour-
aged, particularly with regard to concerns about quality of
life and subjective outcomes.
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